delete National Health (Pharmaceutical Benefits) Regulations (Amendment)
Amendment to the National Health (Pharmaceutical Benefits) Regulations governing Australia's Pharmaceutical Benefits Scheme (PBS). Establishes the regulatory framework for listing, pricing, and supply of subsidized prescription medicines under Medicare. Sets out the criteria for drug listing decisions, patient copayment structures, pharmacy dispensing arrangements, and price negotiation mechanisms between government and pharmaceutical companies.
The PBS represents classic government price fixing and market restriction in pharmaceuticals. It creates a bureaucratic gatekeeping system that rations medicines through political/commercial processes rather than price signals, artificially suppresses drug prices (reducing investment incentives), imposes compliance costs on pharmaceutical companies that ultimately raise consumer prices, and restricts consumer choice. While it provides apparent short-term access benefits, it perpetuates a system where Australians pay for medicines through taxation rather than potentially lower market prices, and its price control mechanisms demonstrably reduce innovation and availability of certain treatments globally. The instrument should be deleted to allow genuine market-based pharmaceutical competition with private insurance and charity mechanisms to address genuine access gaps.